Despite price, rifampin can be a less costly alternative in TB prophylaxis

Organisation: Position: Deadline Date: Location:

While rifampin is a more costly tuberculosis treatment, its shorter treatment length and fewer adverse events resulted in a lower total cost across study sites.

Isoniazid, an inhibitor of mycobacteria cell wall synthesis, is the standard of treatment of latent TB. Rifampin, a more costly medication, is generally reserved for active TB treatment along with ethambutol and pyrazinamide.

This study by researchers at State University of Rio de Janeiro, McGill University, Universtitas Padjadjaran – Indonesia, Korean National Tuberculosis Association, and Centre National Hospitalier Universitaire de Pneumo-Phtisiologie – Benin, demonstrated that while rifampin is more expensive, its shorter treatment length and fewer adverse events resulted in a lower total cost across study sites.

Ultimately this represented a cost savings to the health system of roughly one-third of the cost of isoniazid. The study’s applicability was strengthened by its multi-centred approach that included representative countries across GDP.

The failure to include individual cost burden limited the study’s ability to fully account for possible barriers to treatment.

Abstract
Background: Four months of rifampin treatment for latent tuberculosis infection is safer, has superior treatment completion rates, and is as effective as 9 months of isoniazid. However, daily medication costs are higher for a 4-month rifampin regimen than a 9-month isoniazid regimen.
Objective: To compare health care use and associated costs of 4 months of rifampin and 9 months of isoniazid.
Design: Health system cost comparison using all health care activities recorded during 2 randomized clinical trials. (ClinicalTrials.gov: NCT00931736 and NCT00170209)
Setting: High-income countries (Australia, Canada, Saudi Arabia, and South Korea), middle-income countries (Brazil and Indonesia), and African countries (Benin, Ghana, and Guinea).
Participants: Adults and children with clinical or epidemiologic factors associated with increased risk for developing tuberculosis that warranted treatment for latent tuberculosis infection.
Measurements: Health system costs per participant.
Results: A total of 6012 adults and 829 children were included. In both adults and children, greater health system use and higher costs were observed with 9 months of isoniazid than with 4 months of rifampin. In adults, the ratios of costs of 4 months of rifampin versus 9 months of isoniazid were 0.76 (95% CI, 0.70 to 0.82) in high-income countries, 0.90 (CI, 0.85 to 0.96) in middle-income countries, and 0.80 (CI, 0.78 to 0.81) in African countries. Similar findings were observed in the pediatric population.
Limitation: Costs may have been overestimated because the trial protocol required a minimum number of follow-up visits, although fewer than recommended by many authoritative guidelines.
Conclusion: A 4-month rifampin regimen was safer and less expensive than 9 months of isoniazid in all settings. This regimen could be adopted by tuberculosis programs in many countries as first-line therapy for latent tuberculosis infection.
Primary Funding Source: Canadian Institutes of Health Research.

Authors
Mayara Lisboa Bastos, Jonathon R Campbell, Olivia Oxlade, Menonli Adjobimey, Anete Trajman, Rovina Ruslami, Hee Jin Kim, Joseph Obeng Baah, Brett G Toelle, Richard Long, Vernon Hoeppner, Kevin Elwood, Hamdan Al-Jahdali, Lika Apriani, Andrea Benedetti, Kevin Schwartzman, Dick Menzies

2 Minute Medicine material Annals of Internal Medicine abstract

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.